News on the people who matter.
Healthcare

Isomorphic Labs raises $5 billion to take AI-designed drugs into trials

Greenoaks and Sequoia Capital co-led the round for the DeepMind spinout, which reports positive preclinical results.

Demis Hassabis in glasses, a dark suit and tie, seated behind a microphone and a name card at a press conference, in black and white
Demis Hassabis at the 2024 Nobel Prize press conference in Stockholm. Photo by John Sears / Wikimedia Commons (CC BY-SA 4.0), cropped and converted to black and white

Isomorphic Labs, the artificial intelligence drug-discovery company spun out of Google's DeepMind in 2021, said Tuesday it has raised $5 billion in a Series C round to move its drug candidates toward clinical trials, according to a company announcement.

Greenoaks and Sequoia Capital co-led the round, which follows a $2.1 billion Series B in May, TechCrunch reported. Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the lab was seeking funding at a $50 billion valuation, TechCrunch said.

Andreessen Horowitz joined as a new investor along with several others, and Alphabet put in what the company described as continued significant investment. Every existing backer also took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

The London company says its pipeline is producing results in the lab. Isomorphic said its work is yielding positive preclinical results in internal oncology and immunology programs and in programs with partners. It has struck deals with Eli Lilly, Novartis and Johnson & Johnson, according to TechCrunch.

At the center of the business is a proprietary drug design engine called IsoDDE. The company said the engine combines a suite of simulation AI models that work across multiple therapeutic areas and types of medicine, searching large chemical spaces to help its scientists design molecules with strong drug-like properties. The work builds on AlphaFold, the DeepMind protein-folding model.

The raise is Isomorphic's first since founder and Chief Executive Demis Hassabis left his position as head of DeepMind to focus on drug discovery, a shift that also moved him into a chairman role at DeepMind, TechCrunch reported. Hassabis and John Jumper shared half of the 2024 Nobel Prize in Chemistry for protein structure prediction.

Demis Hassabis and John Jumper seated behind name cards at a press conference table, with a screen behind them
Hassabis, left, and John Jumper at the 2024 Nobel Prize press conference at the Royal Swedish Academy of Sciences. Photo by Jennifer 8. Lee / Wikimedia Commons (CC BY-SA 4.0)

"When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI," Hassabis said in the announcement. He said the round will help the company build foundational biology models and drive its first therapeutic programs toward clinical trials.

Max Jaderberg, Isomorphic's president, said the company's teams pair machine learning researchers with drug hunters. "Every week we are making repeatable scientific advancements enabled by our models," he said.

Proceeds will go toward maturing IsoDDE, expanding into new biology with more advanced models and building a partner network to study the mechanisms of disease, the company said. Isomorphic is also building global infrastructure for AI-led bioengineering.

Neil Mehta, founder and managing partner of Greenoaks, said Isomorphic is building deep learning systems that can predict complex biological behavior and map the route to new medicines. Konstantine Buhler, a partner at Sequoia Capital, said the team is turning advanced AI into a growing portfolio of drug candidates.

Isomorphic, which also has offices in Cambridge, Mass., and Lausanne, Switzerland, said the new money will fund the translational and clinical development infrastructure it needs as its drug candidates advance into trials.

More on drug development and the investors behind it is on our Healthcare and Capital pages.

Sources

  1. company announcement · https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-c-investment-round
  2. TechCrunch reported · https://techcrunch.com/2026/11/17/isomorphic-labs-raises-5b-as-it-looks-to-take-drug-candidates-to-clinical-trials/
  3. 2024 Nobel Prize in Chemistry · https://www.nobelprize.org/prizes/chemistry/2024/summary/
  4. Isomorphic Labs announces Series C investment round (with news release PDF ISOMORPHIC_LABS_FUNDING_17-11-26.pdf) · https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-c-investment-round
  5. Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials · https://techcrunch.com/2026/11/17/isomorphic-labs-raises-5b-as-it-looks-to-take-drug-candidates-to-clinical-trials/
  6. Nobel Prize in Chemistry 2024 - Summary · https://www.nobelprize.org/prizes/chemistry/2024/summary/

Corrections: team@1nfluenc3.com

How we source and correct: Editorial Standards. Spot an error? Corrections.